Residual popliteal vein thrombosis after endovascular treatment of mixed-type lower extremity deep vein thrombosis is relevant to post-thrombotic syndrome

混合型下肢深静脉血栓形成经血管内治疗后残留的腘静脉血栓形成与血栓后综合征相关。

阅读:3

Abstract

OBJECTIVE: Patients with mixed-type lower extremity deep vein thrombosis (DVT) have a higher incidence of post-thrombotic syndrome (PTS) after endovascular treatment (EVT). This study aimed to identify risk factors associated with PTS in these patients after EVT. METHODS: This retrospective study included patients diagnosed with acute mixed-type lower extremity DVT who underwent EVT between January 2020 and December 2022. Patient assessments were conducted using ultrasound examination and the Villalta scale. Baseline characteristics, management details, and follow-up findings were compared between patients who developed PTS and those who did not at 6 months after EVT. Cox regression and nomogram analyses were performed to identify risk factors associated with the development of PTS. RESULTS: The study enrolled 118 patients, of which 103 completed the follow-up. Among them, 24.3% developed post-thrombotic syndrome (PTS) within 6 months. Significant differences between the PTS and non-PTS groups were found concerning residual thrombosis in the popliteal, common femoral, and femoral veins. Multivariate Cox regression analysis indicated that residual popliteal vein thrombosis (RPVT) (hazard ratio [HR], 4.93; 95% confidence interval [CI], 1.61-15.11) and preoperative iliac vein stenosis (HR, 3.21; 95% CI, 1.11-9.33) were significant risk factors for PTS. Additionally, subgroup analysis for preoperative iliac vein stenosis and sensitivity analysis confirmed that RPVT remained a risk factor for PTS (HR, 4.48; 95% CI, 1.27-15.84). CONCLUSIONS: Our study demonstrated a positive association between RPVT and PTS in patients with extensive mixed-type lower extremity DVT after EVT. These findings suggest that intensive monitoring and aggressive therapeutic interventions may be required for patients with RPVT to decrease the risk of PTS.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。